Showing results (271-280 of 291) with videos related to
Sort By:
Pageof 30
BMC Cancer|April 30, 2020
Higher number of multidisciplinary tumor board meetings per case leads to improved clinical outcomeMarius Freytag, Ulrich Herrlinger, Stefan Hauser, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2010
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I studyAnjali Advani, Bertrand Coiffier, Myron S Czuczman, et al.Blood Advances|January 19, 2018
Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myelomaMaximilian Merz, Anna Jauch, Thomas Hielscher, et al.Journal of Gastrointestinal Oncology|July 12, 2023
Impaired immunogenicity after vaccination for SARS-CoV-2 in patients with gastrointestinal cancer: does tumor entity matter?Malte Benedikt Monin, Jens Gabriel Gorny, Moritz Berger, et al.In Vivo (Athens, Greece)|October 30, 2025
Improved Implementation of Tumor Board Decisions: A Retrospective Single Center Observational Study in GermanyJohanna Ernst, Katharina Alfter, Alexander Mustea, et al.Haematologica|April 5, 2015
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trialMaximilian Merz, Hans Salwender, Mathias Haenel, et al.Blood|November 1, 2014
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trialDieter Hoelzer, Jan Walewski, Hartmut Döhner, et al.European Journal of Haematology|April 4, 2017
Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsEMarc-Andrea Baertsch, Jana Schlenzka, Katharina Lisenko, et al.International Journal of Molecular Sciences|June 27, 2024
Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income CountriesAnja Seckinger, Hans Salwender, Hans Martin, et al.Leukemia|March 20, 2015
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myelomaE K Mai, U Bertsch, J Dürig, et al.Pageof 30